

**Abbott Medical Danmark A/S  
Produktionsvej 14  
2600 Glostrup**

**Business Registration No. 17 55 85 01**

**Annual report 2019**

The Annual General Meeting adopted the annual report on 08.06.2020

Chairman of the General Meeting

---

Name: Fredrik Björnulfson

## Contents

	<u>Page</u>
Entity details	3
Statement by Management on the annual report	4
Independent auditor's reports	5
Management commentary	8
Accounting policies	11
Income statement for 2019	16
Balance sheet at 31.12.2019	17
Statement of changes in equity for 2019	19
Notes	20

**Please note that Danish decimal and digit grouping symbols have been used in the financial statements.**

---

## *Entity details*

### **Entity**

Abbott Medical Danmark A/S  
Produktionsvej 14  
DK-2600 Glostrup

Central Business Registration No: 17 55 85 01  
Registered in: Glostrup  
Financial year: 01.01.2019 - 31.12.2019  
Established: 20.01.1994

### **Board of Directors**

Benjamin Edward Oosterbaan, Chairman  
Fredrik Björnulfson  
Flemming Wærn Johannessen

### **Executive Board**

Flemming Wærn Johannessen, Chief Executive Officer

### **Auditors**

Ernst & Young Godkendt Revisionspartnerselskab  
Osvald Helmuths Vej 4  
DK-2000 Frederiksberg

### **Bank**

Bank National Paris, BNP

---

## Statement by Management on the annual report

The Board of Directors and the Executive Board have today considered and approved the annual report of Abbott Medical Danmark A/S for the financial year 01.01.2019 - 31.12.2019.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

It is our opinion that the financial statements give a true and fair view of the Company's financial position at 31.12.2019 and of the results of the Company's operations for the financial year 01.01.2019 - 31.12.2019.

Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 08.06.2020

### Executive Board

Flemming Wærn Johannessen  
Chief Executive Officer

### Board of Directors

Benjamin Edward Oosterbaan  
Chairman

Fredrik Björnulfson

Flemming Wærn Johannessen

## **Independent auditor's reports**

### **To the owners of Abbott Medical Danmark A/S**

#### **Opinion**

We have audited the financial statements of Abbott Medical Danmark A/S for the financial year 1 January – 31 December 2019, which comprise income statement, balance sheet, statement of changes in equity, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2019 and of the results of the Company's operations for the financial year 1 January – 31 December 2019 in accordance with the Danish Financial Statements Act.

#### **Basis of opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Independence**

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

#### **Management's responsibilities for the financial statements**

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

#### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

## Independent auditor's reports

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management

- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

## **Independent auditor's reports**

Copenhagen, 08.06.2020

### **Ernst & Young**

Godkendt Revisionspartnerselskab

CVR-nr. 30 70 02 28

Birgit Morville Schrøder

State Authorised Public Accountant

mne21337

---

## Management commentary

<b>Financial highlights</b>	<b>2019</b>	<b>2018</b>	<b>2017</b>	<b>2016</b>	<b>2015</b>
	<b><u>DKK'000</u></b>	<b><u>DKK'000</u></b>	<b><u>DKK'000</u></b>	<b><u>DKK'000</u></b>	<b><u>DKK'000</u></b>
<b>Key figures</b>					
Revenue	222.315	237.632	191.535		
Gross profit/loss	34.908	42.859	32.263	28.340	21.427
Operating profit/loss	7.722	13.146	10.892	6.682	2.751
Net financials	(205)	711	732	929	887
Profit/loss for the year	5.674	10.223	8.445	5.365	1.692
Total assets	196.036	160.482	122.339	125.014	112.227
Investments in property, and equipment	1.082	4.474	37	22	8
Equity	110.596	104.921	91.610	83.165	77.799
<b>Ratios</b>					
Gross margin (%)	15,7	18,0	16,8		
Net margin (%)	2,6	4,3	4,4		
Return on equity (%)	5,3	10,4	9,7	6,7	2,2
Solvency ratio (%)	56	65	75	66,5	69,3

As a of 2018 the AV/SH division was transferred from Abbott Laboratories A/S and as a consequence of this, 2018 is not comparable with prior year's figures.

Abbott Medical Danmark A/S operated as a commissioner up to 2017 and as a consequence of this, we do not have revenue figures for 2014-2016.



## Management commentary

### Primary activities

The company's activity is the sale of cardiologic medical implants and catheters, mainly produced by other companies within the Abbott Group.

### Development in activities and finances

Revenue for the year amounts to 222.315 thousand compared to 237.632 from last year. Profit after tax amounts to DKK 5.674 thousand versus DKK 10.223 thousand last year.

Sales and profit are impacted by extra sales in December 2018, where customers added the products to their stock, resulting in lower demand in 2019.

Management considers the performance of the financial year satisfactory.

### Uncertainty relating to recognition and measurement

Management evaluates that no particular uncertainties are related to recognition and measurement in connection with the presentation of the annual report.

### Outlook

The company expects revenue at similar level compared to 2019 which is expected to be from DKK 225 - 235 mio and the results will be from DKK 5 - 9 mio.

On March 11, 2020 the World Health Organization (WHO) declared a global pandemic related to coronavirus (COVID-19). During the first quarter of 2020, the coronavirus (COVID-19) pandemic affected Abbott's diversified health care businesses in various ways. Some businesses faced challenges, others have been relatively stable, and still others are performing at the levels required to successfully meet new demands.

Abbott is continually implementing business continuity plans in the face of the global crisis. Due to the critical nature of its products and services, Abbott is generally exempt from governmental orders in Denmark and other countries requiring businesses to cease operations. To protect its employees, the majority of its office-based work is being conducted remotely and the company has implemented strict travel restrictions. Abbott has taken aggressive steps to limit exposure and enhance the safety of its facilities for employees working to continue to supply healthcare products to hospital and other customers.

Due to uncertainties regarding the duration and impact of the current COVID-19 pandemic, Abbott is unable to predict the extent to which the COVID-19 pandemic may have a material effect on its business, financial condition or results of operations.

## **Management commentary**

### **Particular risks**

#### **Operating risks**

The company is not exposed to any special risks besides from what is normal to the business.

#### **Currency risks**

Purchase of goods and services are mainly executed in DKK. To a minor extent, the company is invoiced in EUR, NOK, SEK and USD. Abbott Medical Danmark A/S do not hedge any of these amounts.

## Accounting policies

### Reporting class

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enter-prises (medium).

The accounting policies have been applied consistently with previous years.

### Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the one in effect at the payment date, or the rate at the balance sheet date, are recognised in the income statement as financial income or financial expenses. Property, plant and equipment, intangible assets, inventories and other non-monetary assets that have been purchased in foreign currencies are translated using historical rates.

### Operating leases

Lease payments on operating leases are recognised on a straight-line basis in the income statement over the term of the lease.

### Income statement

#### Revenue

The Company has chosen IAS 11/IAS 18 as interpretation for revenue recognition.

Revenue from goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.

Service agreements are accrued over the term of the agreements.

#### Other operating income/expenses

Other operating income/expenses comprises income of a secondary nature as viewed in relation to the Entity's primary activities.

Other operating income/expenses comprise of income from divestment of divisions.

Gains on the sale of intangible assets are recognised in the income statement under "Other operating income". Gains are calculated as the difference between the selling price less selling expenses and the carrying amount at the time of sale.

#### Costs of goods for resale and consumables

Costs of goods for resale and consumables comprise the consumption of goods for resale and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary write-downs of the relevant inventories.

## Accounting policies

### Other external expenses

Other external expenses include expenses relating to the Entity's ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes write-downs of receivables recognised in current assets.

Other external expenses also include research costs and costs of development projects that do not meet the criteria for recognition in the balance sheet.

### Staff costs

Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc. for entity staff.

### Amortisation, depreciation and impairment losses

Amortisation, depreciation and impairment losses relating to intangible assets and property, plant and equipment comprise amortisation, depreciation and impairment losses for the financial year, calculated on the basis of the residual values and useful lives of the individual assets and impairment testing as well as gains and losses from the sale of intangible assets as well as property, plant and equipment.

### Other financial income

Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme, etc.

### Other financial expenses

Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies as well as tax surcharge under the Danish Tax Prepayment Scheme, etc.

### Income taxes

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.

The Company is jointly taxed with all Danish sister subsidiaries. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).

## Accounting policies

### Balance sheet

#### Property, plant and equipment

Plant and machinery, other fixtures and fittings, tools and equipment as well as leasehold improvements are measured at cost less accumulated depreciation and impairment losses.

Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be put into operation.

The basis of depreciation is cost less estimated residual value after the end of useful life. Straight-line depreciation is made based on the following estimated useful lives of the assets:

Plant and machinery	3-10 years
Other fixtures and fittings, tools and equipment	3-10 years
Leasehold improvements	3-10 years

The residual value is determined at the time of acquisition and are reassessed every year. Where the residual value exceeds the carrying amount of the asset, no further depreciation charges are recognised. In case of changes in the residual value, the effect on the depreciation charges is recognised prospectively as a change in accounting estimates.

For leasehold improvements, assets subject to finance leases and for assets lent to customers recognised as operational lease contracts, the depreciation period cannot exceed the contract period.

For leasehold improvements, assets subject to finance leases and for assets lent to customers recognised as operational lease contracts, the depreciation period cannot exceed the contract period.

Property, plant and equipment are written down to the lower of recoverable amount and carrying amount.

#### Investments

Investments comprise of deposits and receivables from group entrises are presented as other receivables. Investments are measured at amortised cost, usually equalling nominal value less write-downs for bad and doubtful debts.

#### Deferred tax

Deferred tax is recognised on all temporary differences between the carrying amount and tax-based value of assets and liabilities, for which the tax-based value of assets is calculated based on the planned use of each asset.

Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at their estimated realisable value, either as a set-off against deferred tax liabilities or as net tax assets.

#### Inventories

Inventories are measured at the lower of cost using the FIFO method and net realisable value.

Cost of goods for resale and consumables consists of purchase price plus delivery costs.

The net realisable value of inventories is calculated as the estimated selling price less costs incurred to execute sale.

## Accounting policies

### Income tax payable or receivable

Current tax payable or receivable is recognised in the balance sheet, stated as tax calculated on this year's taxable income, adjusted for prepaid tax.

### Receivables

The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables.

Receivables are measured at amortised cost, usually equalling nominal value less write-downs for bad and doubtful debts.

### Prepayments

Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.

### Cash

Cash comprises cash in hand and bank deposits.

Balances in the group's cash pool scheme are not, due to the nature of the scheme, considered cash, but are recognised under 'Receivables from group entities'.

### Equity

#### Proposed dividends

Dividend proposed for the year is recognised as a liability once adopted at the annual general meeting (declaration date). Dividends expected to be distributed for the financial year are presented as a separate item under "Equity".

#### Other payables

Other payables are measured at net realisable value.

#### Other financial liabilities

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.

#### Prepayments received from customers

Prepayments received from customers comprise amounts received from customers prior to delivery of the goods agreed or completion of the service agreed.

#### Omission to present a Cash flow statement

With reference to the section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flow is part of the consolidated cash flow statement for the parent company, Abbott Laboratories, Abbott Park, Illinois, USA.

Consolidated group financial statements including consolidated group cash flow statement may be retrieved from the following webpage: <http://www.abbott.com/investors.html>.

## Accounting policies

### Financial highlights

Financial highlights are defined and calculated in accordance with "Recommendations & Ratios 2015" issued by the Danish Society of Financial Analysts.

<b>Ratios</b>	<b>Calculation formula</b>
Gross margin (%)	$\frac{\text{Gross profit} \times 100}{\text{Revenue}}$
Net margin (%)	$\frac{\text{Profit/loss for the year} \times 100}{\text{Revenue}}$
Return on equity (%)	$\frac{\text{Profit/loss for the year} \times 100}{\text{Average equity}}$
Solvency ratio (%)	$\frac{\text{Equity} \times 100}{\text{Total assets}}$

### Ratios reflect

#### *Gross margin*

The Entity's operating gearing.

#### **Net margin**

The Entity's operating profitability.

#### **Return on equity**

The Entity's return on capital invested in the Entity by the owners.

#### **Solvency ratio**

The financial strength of the Entity.

**Income statement for 2019**

	<u>Notes</u>	<u>2019 DKK</u>	<u>2018 DKK</u>
Revenue		222.315.485	237.631.789
Costs of goods of sale and consumables		(181.048.640)	(186.336.729)
Other external expenses		(6.359.019)	(8.436.020)
<b>Gross profit/loss</b>		<b>34.907.826</b>	<b>42.859.040</b>
Staff costs	1	(25.764.468)	(28.459.131)
Amortisation, depreciation and impairment losses	2	(1.421.857)	(1.254.324)
<b>Operating profit/loss</b>		<b>7.721.501</b>	<b>13.145.585</b>
Other financial income	3	157.039	957.884
Other financial expenses	4	(362.850)	(246.476)
<b>Profit/loss from ordinary activities before tax</b>		<b>7.515.690</b>	<b>13.856.993</b>
Tax on profit/loss from ordinary activities	5	(1.841.517)	(3.634.136)
<b>Profit/loss for the year</b>		<b>5.674.173</b>	<b>10.222.857</b>



**Balance sheet at 31.12.2019**

	<u>Notes</u>	<u>2019</u> <u>DKK</u>	<u>2018</u> <u>DKK</u>
<b>ASSETS</b>			
<b>Fixed assets</b>			
Plant and machinery		1.445.753	2.291.978
Other fixtures and fittings, tools and equipment		246.097	39.160
Leasehold improvements		10.203	23.522
<b>Property, plant and equipment</b>	<b>6</b>	<b><u>1.702.053</u></b>	<b><u>2.354.660</u></b>
<b>Investments</b>			
Receivables from group companies	8	69.311.000	69.313.600
Other receivables		192.853	192.853
<b>Investments</b>		<b><u>69.503.853</u></b>	<b><u>69.506.453</u></b>
<b>Total Fixed Assets</b>		<b><u>71.205.906</u></b>	<b><u>71.861.113</u></b>
<b>Non-fixed assets</b>			
<b>Inventories</b>			
Goods for resale		11.364.296	9.482.626
<b>Inventories</b>		<b><u>11.364.296</u></b>	<b><u>9.482.626</u></b>
<b>Receivables</b>			
Trade receivables		29.862.058	50.317.383
Receivables from group enterprises	8	0	19.160.024
Deferred tax assets	7	259.261	246.996
Income tax receivable		0	589.528
Other Receivables		202.075	48.000
Prepayments		228.101	120.882
<b>Receivables</b>		<b><u>30.551.495</u></b>	<b><u>70.482.813</u></b>
<b>Cash</b>		<b><u>82.914.689</u></b>	<b><u>8.655.155</u></b>
<b>Total non-fixed assets</b>		<b><u>124.830.480</u></b>	<b><u>88.620.594</u></b>
<b>Assets</b>		<b><u>196.036.386</u></b>	<b><u>160.481.707</u></b>

**Balance sheet at 31.12.2019**

	Notes	2019 DKK	2018 DKK
Share capital		1.000.000	1.000.000
Retained earnings		<b>109.595.662</b>	<b>103.921.489</b>
<b>Equity</b>		<b>110.595.662</b>	<b>104.921.489</b>
<b>Current Liabilities</b>			
Trade Payable		1.873.660	1.027.142
Payables to group enterprises	8	60.133.917	24.431.761
Income tax payable		2.041.717	3.924.291
Other payables		21.391.430	26.177.024
<b>Current liabilities other than provisions</b>		<b>85.440.724</b>	<b>55.560.218</b>
<b>Liabilities other than provisions</b>		<b>85.440.724</b>	<b>55.560.218</b>
<b>Equity and liabilities</b>		<b>196.036.386</b>	<b>160.481.707</b>
Related parties with control	8		
Appropriation of profit/loss	9		
Unrecognised rental and lease commitments	10		
Contingent liabilities	11		
Consolidation	12		
Events after the balance sheet date	13		

## Statement of changes in equity for 2019

<b>DKK</b>	<b>Share capital</b>	<b>Retained earnings</b>	<b>Dividend proposed</b>	<b>Total</b>
<b>Equity at 1 January 2018</b>	500.000	91.109.713	0	91.609.713
Transfer, see " note 11 Appropriation of profit	0	10.222.857	0	10.222.857
Capital increase by transfer of AV/SH business	500.000	2.588.919	0	3.088.919
<b>Equity at 31 December 2018</b>	<b>1.000.000</b>	<b>103.921.489</b>	<b>0</b>	<b>104.921.489</b>
Transfer, see " note 11 Appropriation of profit		5.674.173	0	5.674.173
<b>Equity at 31 December 2019</b>	<b>1.000.000</b>	<b>109.595.662</b>	<b>0</b>	<b>110.595.662</b>

<b>Changes in share</b>	<b>2019 DKK</b>	<b>2018 DKK</b>	<b>2017 DKK</b>	<b>2016 DKK</b>	<b>2015 DKK</b>
Share capital beginning of year	1.000.000	500.000	500.000	500.000	500.000
Increase of capital	0	500.000	0	0	0
<b>Share capital end of year</b>	<b>1.000.000</b>	<b>1.000.000</b>	<b>500.000</b>	<b>500.000</b>	<b>500.000</b>

<b>Share capital</b>	<b>Number</b>	<b>Par value DKK</b>	<b>Nominal value DKK</b>
Ordinary shares	1.000	1.000	1.000.000

## Notes

<b>1. Staff costs</b>	<b>2019</b>	<b>2018</b>
	<b><u>DKK</u></b>	<b><u>DKK</u></b>
Wages and salaries	23.414.326	26.071.502
Pension costs	2.233.914	2.289.208
Other social security costs	116.227	98.421
	<b><u>25.764.468</u></b>	<b><u>28.459.131</u></b>
	<b><u>2019</u></b>	<b><u>2018</u></b>
Average number of full-time employees	<b><u>25</u></b>	<b><u>27</u></b>

Remuneration has not been paid to the Board of Directors in the financial year. Management remuneration is not disclosed in accordance with the exemption clause in section 98b of the Danish Financial Statements Act.

<b>2. Amortisation, depreciation and impairment losses</b>	<b>2019</b>	<b>2018</b>
	<b><u>DKK</u></b>	<b><u>DKK</u></b>
Depreciation on property, plant and equipment	1.421.857	1.254.324
	<b><u>1.421.857</u></b>	<b><u>1.254.324</u></b>

<b>3. Other financial income</b>	<b>2019</b>	<b>2018</b>
	<b><u>DKK</u></b>	<b><u>DKK</u></b>
Financial income from group enterprises	161.153	948.694
Currency translation adjustments	(4.114)	9.190
	<b><u>157.039</u></b>	<b><u>957.884</u></b>

## Notes

<b>4. Other financial expenses</b>	<b>2019</b>	<b>2018</b>
	<b><u>DKK</u></b>	<b><u>DKK</u></b>
Financial expenses from group enterprises	4.395	5.075
Other interest expenses	331.142	216.492
Currency translation adjustments	27.313	24.909
	<b><u>362.850</u></b>	<b><u>246.476</u></b>
<b>5. Tax on profit/loss from ordinary activities</b>	<b>2019</b>	<b>2018</b>
	<b><u>DKK</u></b>	<b><u>DKK</u></b>
Current tax	2.041.717	3.924.291
Change in deferred tax	12.265	1.343.100
Adjustment relating to previous years	-212.465	-1.633.255
	<b><u>1.841.517</u></b>	<b><u>3.634.136</u></b>

## Notes

<b>6. Property, plant and equipment</b>	<b>Plant and machinery</b>	<b>Other fixtures and fittings, tools and equipment</b>	<b>Leasehold improve- ments</b>
	<b><u>DKK</u></b>	<b><u>DKK</u></b>	<b><u>DKK</u></b>
Cost at 1 January 2019	3.491.676	315.690	160.994
Additions	828.301	253.588	0
Disposals	(1.413.344)	0	0
<b>Cost at 31 December 2019</b>	<b><u>2.906.633</u></b>	<b><u>569.278</u></b>	<b><u>160.994</u></b>
Depreciation and impairment losses at 1 January 2019	(1.199.698)	(276.530)	(137.472)
Depreciation for the year	(1.366.747)	(41.792)	(13.318)
Reversal regarding disposals	1.105.564	(4.859)	0
<b>Depreciation and impairment losses at 31 December 2019</b>	<b><u>(1.460.881)</u></b>	<b><u>(323.181)</u></b>	<b><u>(150.790)</u></b>
<b>Carrying amount at 31 December 2019</b>	<b><u>1.445.752</u></b>	<b><u>246.097</u></b>	<b><u>10.203</u></b>

Plant and machinery mainly consist of equipment lent to customers recognized as operational lease contracts.

## Notes

<b>7. Deferred tax</b>	<b>2019</b>	<b>2018</b>
	<b><u>DKK</u></b>	<b><u>DKK</u></b>
Deferred tax at 1 January	246.996	1.590.096
Adjustment of the deferred tax for the year	12.265	(1.343.100)
	<b><u>259.261</u></b>	<b><u>246.996</u></b>
The deferred tax asset relates to:		
Property, plant and equipment	259.261	246.996
Provisions	0	0
	<b><u>259.261</u></b>	<b><u>246.996</u></b>

## Notes

### 8. Related parties

#### Related parties with a controlling interest

The following related parties have a controlling interest in Abbott Medical Danmark A/S:

<b>Name</b>	<b>Registered office</b>	<b>Basis of influence</b>
Abbott Laboratories	Abbott Park, Illinois, USA	Ultimate Parent
Abbott Laboratories A/S	Denmark	Parent

#### Transactions with related parties

<b>Related party</b>	<b>Country</b>	<b>Revenue</b>	<b>2019 DKK</b>	<b>2018</b>
<b>SJM Coordination center BVBA</b>	<b>Belgium</b>	Expense recharge	980.419	7.199.415
		Management fee	7.294.329	11.000.905
<b>SJM LLC</b>	<b>USA</b>	Interest	161.148	948.694
<b>Abbott Vascular Netherlands</b>	<b>Netherland</b>	Expense recharge	146.257	0
<b>Total</b>			<b>8.582.153</b>	<b>19.149.014</b>

<b>Related party</b>	<b>Country</b>	<b>Cost</b>	<b>2019 DKK</b>	<b>2018 DKK</b>
<b>SJM Coordination center BVBA</b>	<b>Belgium</b>	Expense recharge	1.425.547	131.359
		Product purchase	145.196.985	175.151.863
<b>ABT Labs Finance BV Abbott Vascular Netherlands</b>	<b>Netherland</b>	Interest	4.395	5.075
	<b>Netherland</b>	Expense recharge	597	0
		Product purchase	36.343.265	0
<b>Abbott Laboratories A/S</b>	<b>Denmark</b>	Expense recharge	4.033.837	0
<b>Grand Total</b>			<b>187.004.626</b>	<b>175.288.297</b>

As of 1/1-2018 Abbott Laboratories A/S has transferred their AV/SH division to Abbott Medical as a tax-free transaction, through a capital increase.



## Notes

### Receivables from affiliated companies

<b>Related party</b>	<b>Country</b>	<b>2019 DKK</b>	<b>2018 DKK</b>
Abbott Lab Finance BV	Belgium	0	6.462.534
Abbott Laboratories A/S	Denmark	0	12.697.490
Abbott Laboratories	USA	69.311.000	0
SJM Inc, LLC	USA	0	69.313.600
<b>Grand Total</b>		<b>69.311.000</b>	<b>88.473.624</b>

### Payables to affiliated companies

<b>Related party</b>	<b>Country</b>	<b>2019 DKK</b>	<b>2018 DKK</b>
SJM Coordination Center BVBA	Belgium	60.248.265	22.757.207
Abbott Laboratories A/S	Denmark	(37.327)	
Abbott Vascular Netherlands BV	Netherland	(77.021)	1.674.554
<b>Grand Total</b>		<b>60.133.917</b>	<b>24.431.761</b>

## 9. Appropriation of profit/loss

	<b>2019 DKK</b>	<b>2018 DKK</b>
<b>Recommended appropriation of profit/loss</b>		
Transferred to reserves under equity	5.674.173	10.222.857
	<b>5.674.173</b>	<b>10.222.857</b>

## 10. Unrecognised rental and lease commitments

	<b>2019 DKK</b>	<b>2018 DKK</b>
Commitments under rental agreements or leases until expiry	3.061.665	1.712.915
<i>Due within the next 12 months</i>	1.301.069	978.356

## Notes

### 11. Contingent liabilities

The Company participates in a Danish joint taxation arrangement with Danish sister subsidiaries, with Abbott Laboratories A/S as the management company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Company is therefore liable from the financial year 2013 for income taxes etc for the jointly taxed companies and from 01.07.2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed companies

### 12. Consolidation

Name and registered office of the Parent preparing consolidated financial statements:

Abbott Laboratories, Abbott Park, Illinois, USA

<https://www.abbottinvestor.com/financials/annual-reports>

### 13. Events after the balance sheet date

See comments regarding COVID-19 in the Management commentary under Outlook. No other events materially affecting the Company's financial position have occurred subsequent to the financial year-end.